https://www.biopharmawatch.com/news/HSCS/heartsciences-fiscal-2026-annual-report BiopharmaWatch en 2026-07-23T21:15:00.000Z HeartSciences Files Its Fiscal 2026 Annual Report on Form 10-K https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-q2-2026-results-announcement BiopharmaWatch en 2026-07-23T21:15:00.000Z Rapid Micro Biosystems to Announce Second Quarter 2026 Financial Results on August 7, 2026 https://www.biopharmawatch.com/news/KRYS/krystal-biotech-q2-2026-financial-results BiopharmaWatch en 2026-07-23T21:00:00.000Z Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026 https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-merger-update-cash-dividend BiopharmaWatch en 2026-07-23T20:33:00.152Z VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience https://www.biopharmawatch.com/news/ALGN/align-technology-innovations-invisalign-treatment-planning BiopharmaWatch en 2026-07-23T20:30:00.000Z Align Technology Announces New Innovations to Advance Invisalign® Treatment Planning and Enhance Patient Engagement Through Its Integrated Align™ Digital Platform https://www.biopharmawatch.com/news/CVRX/cvrx-second-quarter-2026-results-conference-call BiopharmaWatch en 2026-07-23T20:30:00.000Z CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026 https://www.biopharmawatch.com/news/PRME/prime-medicine-fda-clearance-pm577a-wilson-disease BiopharmaWatch en 2026-07-23T20:18:32.766Z Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease https://www.biopharmawatch.com/news/IMVT/immunovant-financial-results-q1-2026-business-update BiopharmaWatch en 2026-07-23T20:18:03.631Z Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 https://www.biopharmawatch.com/news/ABVX/abivax-strengthens-commercial-capabilities-leadership-appointments BiopharmaWatch en 2026-07-23T20:17:50.073Z Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments https://www.biopharmawatch.com/news/ROIV/roivant-financial-results-business-update-august-2026 BiopharmaWatch en 2026-07-23T20:17:28.055Z Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 https://www.biopharmawatch.com/news/GEHC/ge-healthcare-cfo-transition-q2-2026-results BiopharmaWatch en 2026-07-23T20:15:00.000Z GE HealthCare announces CFO transition; reports preliminary second quarter 2026 financial results and reaffirms guidance reflecting business momentum https://www.biopharmawatch.com/news/EW/edwards-lifesciences-q2-results-2026 BiopharmaWatch en 2026-07-23T20:15:00.000Z Edwards Lifesciences Reports Second Quarter Results https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-conference-call-q2-2026 BiopharmaWatch en 2026-07-23T20:10:00.000Z Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/AORT/artivion-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-23T20:10:00.000Z Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ABBV/genmab-abbvie-phase-3-epcore-dlbcl-1-trial-update BiopharmaWatch en 2026-07-23T20:05:00.000Z Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-q2-2026-results BiopharmaWatch en 2026-07-23T20:05:00.000Z Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026 https://www.biopharmawatch.com/news/THC/tenet-reports-strong-q2-2026-results BiopharmaWatch en 2026-07-23T20:05:00.000Z Tenet Reports Strong Second Quarter 2026 Results; Raises 2026 Financial Outlook https://www.biopharmawatch.com/news/HYPR/hyperfine-announces-q2-2026-financial-results BiopharmaWatch en 2026-07-23T20:05:00.000Z Hyperfine, Inc. to Announce Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-leadership-hiring-promotions BiopharmaWatch en 2026-07-23T20:05:00.000Z Neurocrine Biosciences Announces Key Leadership Hiring, Promotions https://www.biopharmawatch.com/news/HYFT/mindwalk-showcases-reefiq-ai-drug-discovery-amd BiopharmaWatch en 2026-07-23T20:02:00.000Z MindWalk Showcases ReefIQ™ for AI Drug Discovery at AMD Advancing AI https://www.biopharmawatch.com/news/MGNX/macrogenics-phase-1-study-update-mgc026 BiopharmaWatch en 2026-07-23T20:01:00.000Z MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026 https://www.biopharmawatch.com/news/HTFL/heartflow-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-23T20:01:00.000Z Heartflow to Report Second Quarter 2026 Financial Results on August 13, 2026 https://www.biopharmawatch.com/news/ATRC/atricure-reports-q2-2026-financial-results BiopharmaWatch en 2026-07-23T20:01:00.000Z AtriCure Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/DCTH/delcath-systems-second-quarter-2026-earnings-call BiopharmaWatch en 2026-07-23T20:01:00.000Z Delcath Systems to Host Second Quarter 2026 Earnings Call https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-q2-2026-results-call BiopharmaWatch en 2026-07-23T20:01:00.000Z Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026 https://www.biopharmawatch.com/news/ABBV/epcore-dlbcl-1-trial-results-abbv BiopharmaWatch en 2026-07-23T20:00:00.000Z Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) https://www.biopharmawatch.com/news/CYTK/cytokinetics-second-quarter-results-august-2026 BiopharmaWatch en 2026-07-23T20:00:00.000Z Cytokinetics to Announce Second Quarter Results on August 6, 2026 https://www.biopharmawatch.com/news/GMAB/genmab-abbvie-phase-3-epcore-dlbcl-1-trial-clarification BiopharmaWatch en 2026-07-23T20:00:00.000Z Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) https://www.biopharmawatch.com/news/EVO/evotec-selects-navan-global-expense-management BiopharmaWatch en 2026-07-23T16:59:00.000Z Resumen: Evotec elige a Navan para unificar la gestión mundial de los pagos y viáticos https://www.biopharmawatch.com/news/EVO/evotec-selects-navan-global-travel-expense-management BiopharmaWatch en 2026-07-23T16:59:00.000Z Riassunto: Evotec sceglie Navan per unificare a livello globale viaggi, pagamenti e gestione delle spese https://www.biopharmawatch.com/news/EVO/evotec-selects-navan-global-travel-management BiopharmaWatch en 2026-07-23T16:59:00.000Z Samenvatting: Evotec selecteert Navan om het globale beheer van reizen, betalingen en uitgaven een te maken https://www.biopharmawatch.com/news/EVO/evotec-selects-navan-for-expense-management BiopharmaWatch en 2026-07-23T16:58:00.000Z Evotec entscheidet sich für Navan zur Vereinheitlichung des Managements von Reisespesen und Ausgaben https://www.biopharmawatch.com/news/EVO/evotec-navan-global-travel-management BiopharmaWatch en 2026-07-23T16:58:00.000Z Evotec choisit Navan pour unifier la gestion mondiale des voyages, des paiements et des notes de frais https://www.biopharmawatch.com/news/OLMA/costa-bingo-pros-cons-austria BiopharmaWatch en 2026-07-23T16:32:49.000Z Costa Bingo Pros And Cons For Austria: Games, Bonuses, And Payout Speed https://www.biopharmawatch.com/news/OPK/opko-health-report-q2-2026-results BiopharmaWatch en 2026-07-23T16:30:00.000Z OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026 https://www.biopharmawatch.com/news/OKYO/okyo-pharma-director-share-purchase BiopharmaWatch en 2026-07-23T16:00:00.000Z OKYO Pharma Announces Purchase of Shares by Director https://www.biopharmawatch.com/news/OMDA/omada-health-q2-2026-results-conference-call BiopharmaWatch en 2026-07-23T15:27:00.000Z UPDATE - Omada Health to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 6, 2026 https://www.biopharmawatch.com/news/MENS/jyong-biotech-global-bph-market-opportunity BiopharmaWatch en 2026-07-23T14:52:00.000Z Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships https://www.biopharmawatch.com/news/INDV/indivior-report-q2-2026-financial-results-webcast BiopharmaWatch en 2026-07-23T14:00:00.000Z Indivior to Report Second Quarter 2026 Financial Results and Host Webcast https://www.biopharmawatch.com/news/HSTM/healthstream-second-quarter-2026-earnings-call BiopharmaWatch en 2026-07-23T13:25:00.000Z HealthStream to Host Second Quarter 2026 Earnings Conference Call https://www.biopharmawatch.com/news/IMNN/imunon-imnn-001-data-aacr-conference BiopharmaWatch en 2026-07-23T13:25:00.000Z IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development https://www.biopharmawatch.com/news/QDEL/beyond-fentanyl-drug-crisis-changing BiopharmaWatch en 2026-07-23T13:21:00.000Z Beyond Fentanyl: How the Drug Crisis Is Changing https://www.biopharmawatch.com/news/LGVN/deborah-ascheim-elected-longeveron-board BiopharmaWatch en 2026-07-23T13:15:00.000Z Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors https://www.biopharmawatch.com/news/OMDA/omada-health-q2-2026-results-conference-call BiopharmaWatch en 2026-07-23T13:05:44.995Z Omada Health to Announce First Quarter 2026 Financial Results and Host Conference Call on August 6, 2026 https://www.biopharmawatch.com/news/OM/outset-medical-q2-2026-financial-results BiopharmaWatch en 2026-07-23T13:05:31.212Z Outset Medical to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 https://www.biopharmawatch.com/news/HYFT/mindwalk-holdings-revenue-growth-recurring-contracts BiopharmaWatch en 2026-07-23T13:05:00.000Z An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers https://www.biopharmawatch.com/news/MYGN/myriad-genetics-q2-2026-financial-results BiopharmaWatch en 2026-07-23T13:05:00.000Z Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026 https://www.biopharmawatch.com/news/NVO/crux-novo-nordisk-access-wegovy-obesity-medications BiopharmaWatch en 2026-07-23T13:01:00.000Z Crux Collaborates with Novo Nordisk to Offer Access to Wegovy® and Other Obesity Management Medications https://www.biopharmawatch.com/news/NVCT/nuvectis-ciprocopan-approval-china-pnh BiopharmaWatch en 2026-07-23T13:00:00.000Z Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors https://www.biopharmawatch.com/news/BIO/bio-rad-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-23T13:00:00.000Z Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026 https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-9-million-offering BiopharmaWatch en 2026-07-23T12:45:00.000Z China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering https://www.biopharmawatch.com/news/AIDX/2020-biolabs-standstill-agreement-streeterville-capital BiopharmaWatch en 2026-07-23T12:31:00.000Z 20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock https://www.biopharmawatch.com/news/LNTH/lantheus-second-quarter-2026-earnings-call BiopharmaWatch en 2026-07-23T12:30:00.000Z Lantheus to Host Second Quarter 2026 Earnings Conference Call and Webcast on August 6, 2026, at 8:00 a.m. Eastern Time https://www.biopharmawatch.com/news/ICUI/icu-medical-q2-2026-earnings-call BiopharmaWatch en 2026-07-23T12:30:00.000Z ICU Medical Announces Time of Second Quarter 2026 Earnings Conference Call https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-fda-510k-submission BiopharmaWatch en 2026-07-23T12:30:00.000Z Intelligent Bio Solutions Achieves Key Milestone Ahead of Planned FDA 510(k) Submission, Advancing Toward Planned U.S. Market Entry https://www.biopharmawatch.com/news/FEED/envue-medical-navigation-platform-deployment BiopharmaWatch en 2026-07-23T12:30:00.000Z ENvue Medical Deploys Additional Navigation Platform with Existing Customer, A Leading North Texas Medical Center https://www.biopharmawatch.com/news/WVE/wave-life-sciences-q2-2026-financial-results-webcast BiopharmaWatch en 2026-07-23T12:30:00.000Z Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026 https://www.biopharmawatch.com/news/HALO/halozyme-report-q2-2026-results BiopharmaWatch en 2026-07-23T12:30:00.000Z Halozyme to Report Second Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/ALMR/alzpath-alamar-strategic-agreement-clinical-diagnostics BiopharmaWatch en 2026-07-23T12:30:00.000Z ALZpath Broadens Strategic Agreement with Alamar Biosciences to Advance Clinical Diagnostics for Alzheimer's Disease https://www.biopharmawatch.com/news/BBLG/bone-biologics-mid-year-update-2026 BiopharmaWatch en 2026-07-23T12:08:58.131Z Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities https://www.biopharmawatch.com/news/IMDX/imdex-graftassure-assay-kidney-graft-saving-drug BiopharmaWatch en 2026-07-23T12:08:41.675Z iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication https://www.biopharmawatch.com/news/APYX/apyx-medical-q2-2026-financial-results-release BiopharmaWatch en 2026-07-23T12:08:26.382Z Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/LTRN/lantern-pharma-uspto-patent-allowance-ltrn BiopharmaWatch en 2026-07-23T12:01:00.000Z Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers https://www.biopharmawatch.com/news/ARDX/ardelyx-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-23T12:01:00.000Z Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/ARDT/ardent-health-ambient-ai-milestone BiopharmaWatch en 2026-07-23T12:00:00.000Z Ardent Health surpasses 1 million patient encounters supported by ambient AI https://www.biopharmawatch.com/news/ESTA/establishment-labs-q2-2026-financial-results-announcement BiopharmaWatch en 2026-07-23T12:00:00.000Z Establishment Labs® to Announce Second Quarter 2026 Financial Results on August 6 https://www.biopharmawatch.com/news/A/agilent-eu-approval-pd-l1-ihc-22c3 BiopharmaWatch en 2026-07-23T12:00:00.000Z Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma https://www.biopharmawatch.com/news/RVTY/revvity-t-spot-tb-automated-platform-development BiopharmaWatch en 2026-07-23T12:00:00.000Z Revvity Announces Development of High-Throughput T-SPOT.TB Automated Platform for Clinical Labs https://www.biopharmawatch.com/news/CNTN/canton-strategic-holdings-sale-gravitas-life-sciences BiopharmaWatch en 2026-07-23T12:00:00.000Z Canton Strategic Holdings, Inc. Announces Sale of Gravitas Life Sciences, LLC https://www.biopharmawatch.com/news/CYRX/cryoport-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-23T12:00:00.000Z Cryoport to Report Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/EHC/encompass-health-dividend-increase-2026 BiopharmaWatch en 2026-07-23T12:00:00.000Z Encompass Health increases and declares dividend on common stock https://www.biopharmawatch.com/news/YDES/yd-bio-eg-biomed-bio-asia-taiwan-2026-exhibition BiopharmaWatch en 2026-07-23T12:00:00.000Z YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services https://www.biopharmawatch.com/news/HCWB/hcw-biologics-tetravalent-t-cell-engager-clinical-trials-2027 BiopharmaWatch en 2026-07-23T12:00:00.000Z HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027 https://www.biopharmawatch.com/news/PETS/petmeds-sale-leaseback-headquarters-distribution-center BiopharmaWatch en 2026-07-23T12:00:00.000Z PetMeds Announces Proposed Sale-Leaseback of Headquarters and Distribution Center Buildings for $37 Million https://www.biopharmawatch.com/news/COLL/collegium-report-second-quarter-2026-results BiopharmaWatch en 2026-07-23T12:00:00.000Z Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-fda-orphan-drug-designation-ikt-001 BiopharmaWatch en 2026-07-23T12:00:00.000Z Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH https://www.biopharmawatch.com/news/XERS/xeris-biopharma-q2-2026-financial-results BiopharmaWatch en 2026-07-23T11:30:00.000Z Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/VSTM/verastem-oncology-q2-2026-financial-results BiopharmaWatch en 2026-07-23T11:30:00.000Z Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/NVCT/ciprocopan-approval-china-pnh-treatment BiopharmaWatch en 2026-07-23T11:30:00.000Z Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors https://www.biopharmawatch.com/news/AMIX/autonomix-medical-us-patent-precision-neuromodulation BiopharmaWatch en 2026-07-23T11:30:00.000Z Autonomix Medical Secures New U.S. Patent Strengthening Next-Generation Precision Neuromodulation Platform https://www.biopharmawatch.com/news/BKD/brookdale-senior-living-most-loved-workplace-certification BiopharmaWatch en 2026-07-23T11:17:00.000Z Brookdale Senior Living Earns Certified Most Loved Workplace® Recognition https://www.biopharmawatch.com/news/ACB/safari-flower-eu-gmp-certification-aurora-cannabis BiopharmaWatch en 2026-07-23T11:05:00.000Z Safari Flower Company, a Wholly Owned Subsidiary of Aurora Cannabis, Receives EU-GMP Certification at Niagara Facility https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-dorothy-gemmell-board-appointment BiopharmaWatch en 2026-07-23T11:05:00.000Z Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors https://www.biopharmawatch.com/news/NVCR/novocure-reports-second-quarter-2026-results BiopharmaWatch en 2026-07-23T11:00:00.000Z Novocure Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/INSM/insmed-second-quarter-2026-financial-results-call BiopharmaWatch en 2026-07-23T11:00:00.000Z Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026 https://www.biopharmawatch.com/news/SHC/sotera-health-second-quarter-2026-earnings-release BiopharmaWatch en 2026-07-23T11:00:00.000Z Sotera Health Announces Second-Quarter 2026 Earnings Release Date https://www.biopharmawatch.com/news/TLRY/tilray-launches-zonna-thc-pouches BiopharmaWatch en 2026-07-23T11:00:00.000Z Tilray Brands Launches ZONNA, Introducing New THC Pouches for Cannabis Consumers https://www.biopharmawatch.com/news/OKYO/okyo-pharma-ceo-share-purchase BiopharmaWatch en 2026-07-23T11:00:00.000Z OKYO Pharma Announces Purchase of Shares by Chief Executive Officer https://www.biopharmawatch.com/news/VRXA/veraxa-biotech-appoints-christoph-erkel-cso BiopharmaWatch en 2026-07-23T11:00:00.000Z VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio https://www.biopharmawatch.com/news/DGX/quest-diagnostics-q2-2026-financial-results BiopharmaWatch en 2026-07-23T10:45:00.000Z Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026 https://www.biopharmawatch.com/news/TFX/teleflex-second-quarter-2026-earnings-call BiopharmaWatch en 2026-07-23T10:30:00.000Z Teleflex Announces Second Quarter 2026 Earnings Conference Call Information https://www.biopharmawatch.com/news/UTHR/united-therapeutics-appoints-victor-dzau-board BiopharmaWatch en 2026-07-23T10:30:00.000Z United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors https://www.biopharmawatch.com/news/AVAH/aveanna-second-quarter-2026-earnings-release BiopharmaWatch en 2026-07-23T10:30:00.000Z Aveanna Announces Second Quarter 2026 Earnings Release Date and Conference Call https://www.biopharmawatch.com/news/NEUP/scancell-neuphoria-merger-agreement-financing BiopharmaWatch en 2026-07-23T10:11:00.000Z Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing https://www.biopharmawatch.com/news/ONC/beone-medicines-us-manufacturing-expansion BiopharmaWatch en 2026-07-23T10:00:00.000Z BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines https://www.biopharmawatch.com/news/WST/west-pharmaceutical-second-quarter-2026-results BiopharmaWatch en 2026-07-23T10:00:00.000Z West Reports Second-Quarter 2026 Results https://www.biopharmawatch.com/news/TDOC/teladoc-one-new-model-virtual-care BiopharmaWatch en 2026-07-23T10:00:00.000Z Teladoc Health introduces a virtual care practice built around the person, shaping a new era of connected care https://www.biopharmawatch.com/news/EVO/evotec-selects-navan-travel-expense-management BiopharmaWatch en 2026-07-23T07:00:00.000Z Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management https://www.biopharmawatch.com/news/IPHA/innate-pharma-bladder-cancer-panel-btig-conference BiopharmaWatch en 2026-07-23T05:00:00.000Z Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference https://www.biopharmawatch.com/news/ARGX/argenx-half-year-2026-financial-results-update BiopharmaWatch en 2026-07-23T05:00:00.000Z argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update https://www.biopharmawatch.com/news/CUVL/clinuvel-strategic-reorganisation-us-markets BiopharmaWatch en 2026-07-23T04:10:00.000Z CLINUVEL implements strategic reorganisation to refocus on U.S. markets https://www.biopharmawatch.com/news/DXCM/dexcom-first-participant-fda-tempo-pilot-program BiopharmaWatch en 2026-07-22T21:15:00.000Z Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program https://www.biopharmawatch.com/news/EHTH/ehealth-second-quarter-2026-earnings-call BiopharmaWatch en 2026-07-22T21:15:00.000Z eHealth, Inc. to Hold Second Quarter 2026 Earnings Call on August 4 at 5:00 p.m. Eastern Time https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-q2-2026-results-conference-call BiopharmaWatch en 2026-07-22T21:05:00.000Z Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026 https://www.biopharmawatch.com/news/HYFT/mindwalk-holdings-fiscal-2026-results BiopharmaWatch en 2026-07-22T20:54:00.000Z MindWalk Holdings Corp. Reports Fiscal 2026 Results: Revenue Up 46% as the Company Completes Its Pivot to Bio-Native AI Infrastructure https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-avoe-oncology-casdatifan-tivozanib BiopharmaWatch en 2026-07-22T20:35:00.000Z Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients https://www.biopharmawatch.com/news/EXEL/exelixis-second-quarter-2026-results-release BiopharmaWatch en 2026-07-22T20:30:00.000Z Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026 https://www.biopharmawatch.com/news/PFE/fda-priority-review-pfizer-talzenna-xtandi BiopharmaWatch en 2026-07-22T20:30:00.000Z FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer https://www.biopharmawatch.com/news/RCUS/arcus-summit-collaboration-kidney-cancer-trial BiopharmaWatch en 2026-07-22T20:30:00.000Z Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer https://www.biopharmawatch.com/news/SER/serina-therapeutics-appoints-farrell-simon-board BiopharmaWatch en 2026-07-22T20:30:00.000Z Serina Therapeutics Appoints Farrell Simon to its Board of Directors https://www.biopharmawatch.com/news/MEDP/medpace-holdings-q2-2026-results BiopharmaWatch en 2026-07-22T20:15:00.000Z Medpace Holdings, Inc. Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/CYH/community-health-systems-q2-2026-results BiopharmaWatch en 2026-07-22T20:15:00.000Z Community Health Systems, Inc. Announces Second Quarter Ended June 30, 2026 Results https://www.biopharmawatch.com/news/MOH/molina-healthcare-q2-2026-financial-results BiopharmaWatch en 2026-07-22T20:15:00.000Z Molina Healthcare Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/OSUR/orasure-second-quarter-2026-financial-results-call BiopharmaWatch en 2026-07-22T20:10:00.000Z OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th https://www.biopharmawatch.com/news/BTMD/biote-schedules-q2-2026-financial-results-release BiopharmaWatch en 2026-07-22T20:05:00.000Z Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call https://www.biopharmawatch.com/news/VIR/vir-biotechnology-conference-call-q2-2026 BiopharmaWatch en 2026-07-22T20:05:00.000Z Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/RVMD/revolution-medicines-daraxonrasib-fda-review BiopharmaWatch en 2026-07-22T20:05:00.000Z Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-q2-2026-financial-results BiopharmaWatch en 2026-07-22T20:05:00.000Z Cytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/ACB/aurora-cannabis-first-quarter-2027-conference-call BiopharmaWatch en 2026-07-22T20:05:00.000Z Aurora Cannabis to Host First Quarter 2027 Investor Conference Call https://www.biopharmawatch.com/news/AVNS/avanos-medical-stockholders-approve-acquisition BiopharmaWatch en 2026-07-22T20:05:00.000Z Avanos Medical, Inc. Stockholders Approve Acquisition by American Industrial Partners https://www.biopharmawatch.com/news/NUVB/nuvation-bio-q2-2026-financial-results-update BiopharmaWatch en 2026-07-22T20:05:00.000Z Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-07-22T20:05:00.000Z Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026 https://www.biopharmawatch.com/news/SGHT/sight-sciences-q2-2026-financial-results-report BiopharmaWatch en 2026-07-22T20:05:00.000Z Sight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-earnings-call-august-2026 BiopharmaWatch en 2026-07-22T20:02:00.000Z Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 6, 2026 https://www.biopharmawatch.com/news/VSTM/verastem-target-d-202-trial-vs-7375-nsclc BiopharmaWatch en 2026-07-22T20:01:00.000Z Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/TKNO/teknova-q2-2026-financial-results-report BiopharmaWatch en 2026-07-22T20:01:00.000Z Teknova to Report Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-q2-2026-financial-results BiopharmaWatch en 2026-07-22T20:01:00.000Z Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/GUTS/fractyl-health-investor-events-2026 BiopharmaWatch en 2026-07-22T20:01:00.000Z Fractyl Health to Participate in Upcoming Investor Events https://www.biopharmawatch.com/news/CARL/carlsmed-q2-2026-financial-results-report BiopharmaWatch en 2026-07-22T20:01:00.000Z Carlsmed Inc. to Report Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/PRLD/precision-degrader-antibody-conjugates-targeted-therapeutics BiopharmaWatch en 2026-07-22T19:14:00.000Z Precision degrader-antibody conjugates (pDACs) with a SMARCA2/4 dual payload as targeted therapeutics for acute myeloid leukemia https://www.biopharmawatch.com/news/PEN/thunder-study-penumbra-thunderbolt-stroke-care BiopharmaWatch en 2026-07-22T18:35:00.000Z THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care https://www.biopharmawatch.com/news/IMRX/david-caouette-joins-immuneering BiopharmaWatch en 2026-07-22T18:23:21.000Z David Caouette https://www.biopharmawatch.com/news/CHRS/coherus-oncology-q2-2026-financial-results BiopharmaWatch en 2026-07-22T17:36:00.000Z Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-renmark-roadshow-participation BiopharmaWatch en 2026-07-22T16:31:15.000Z Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series https://www.biopharmawatch.com/news/VALN/valneva-first-half-2026-financial-results BiopharmaWatch en 2026-07-22T15:45:00.000Z Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026 https://www.biopharmawatch.com/news/LLY/lilly-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-22T14:00:00.000Z Lilly confirms date and conference call for second-quarter 2026 financial results announcement https://www.biopharmawatch.com/news/OKYO/okyo-pharma-share-purchase-development-officer BiopharmaWatch en 2026-07-22T14:00:00.000Z OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director https://www.biopharmawatch.com/news/CPHI/china-pharma-pricing-5-million-offering BiopharmaWatch en 2026-07-22T13:25:00.000Z China Pharma Announces Pricing of $5 Million Registered Direct Offering https://www.biopharmawatch.com/news/MMED/minimed-flex-available-medicare-beneficiaries BiopharmaWatch en 2026-07-22T13:05:00.000Z MiniMed Flex™ Now Available to Medicare and Medicare Advantage Beneficiaries https://www.biopharmawatch.com/news/CODX/cosara-clinical-studies-tuberculosis-test-india BiopharmaWatch en 2026-07-22T13:00:00.000Z Co-Diagnostics Joint Venture CoSara Initiates Clinical Studies in India for Tuberculosis Test on PCR Platform https://www.biopharmawatch.com/news/CVS/cvs-health-strengthening-communities-massachusetts BiopharmaWatch en 2026-07-22T13:00:00.000Z CVS Health Helping to Strengthen Communities Across Massachusetts https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-next-gen-adc-opportunity BiopharmaWatch en 2026-07-22T12:40:00.000Z Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity https://www.biopharmawatch.com/news/ARTL/non-prescription-cbd-products-fall-short-art12-11 BiopharmaWatch en 2026-07-22T12:39:00.000Z New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition https://www.biopharmawatch.com/news/KAPA/kairos-pharma-bayer-collaboration-xofigo-prostate-cancer BiopharmaWatch en 2026-07-22T12:35:00.000Z Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-07-22T12:30:00.000Z Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SDGR/schrodinger-announces-q2-2026-results BiopharmaWatch en 2026-07-22T12:30:00.000Z Schrödinger to Announce Second Quarter 2026 Financial Results on August 5 https://www.biopharmawatch.com/news/PRGO/perrigo-second-quarter-2026-financial-results-release BiopharmaWatch en 2026-07-22T12:30:00.000Z Perrigo to Release Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/BIAF/bioaffinity-pictor-partnership-lung-diagnostics BiopharmaWatch en 2026-07-22T12:08:00.000Z bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD https://www.biopharmawatch.com/news/PFE/bluesight-pfizer-partner-rfid-medications-hospitals BiopharmaWatch en 2026-07-22T12:05:00.000Z Bluesight and Pfizer Partner to Provide Source-Tagged RFID Medications to Hospital Pharmacies https://www.biopharmawatch.com/news/LABT/lakewood-amendex-nu-3-resistance-data BiopharmaWatch en 2026-07-22T12:02:00.000Z Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria https://www.biopharmawatch.com/news/MCK/mckesson-quarterly-dividend-increase-2026 BiopharmaWatch en 2026-07-22T12:00:00.000Z McKesson Corporation Raises Quarterly Dividend by 15% to $0.94 Per Share https://www.biopharmawatch.com/news/DRIO/dario-announces-23-5-million-offering BiopharmaWatch en 2026-07-22T12:00:00.000Z Dario Announces Pricing of a $23.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/MNPR/monopar-rolling-nda-alxn1840-wilson-disease BiopharmaWatch en 2026-07-22T12:00:00.000Z Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease https://www.biopharmawatch.com/news/PCRX/pacira-report-q2-2026-results BiopharmaWatch en 2026-07-22T12:00:00.000Z Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026 https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-casey-tansey-retirement BiopharmaWatch en 2026-07-22T12:00:00.000Z Inspire Medical Systems, Inc. Announces Retirement of Casey M. Tansey from its Board of Directors https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-nova-2-trial-results-timing BiopharmaWatch en 2026-07-22T12:00:00.000Z LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-presentation-canaccord-conference BiopharmaWatch en 2026-07-22T11:40:00.000Z TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference https://www.biopharmawatch.com/news/USPH/us-physical-therapy-q2-2026-earnings-release BiopharmaWatch en 2026-07-22T11:30:00.000Z U.S. Physical Therapy, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call Dates https://www.biopharmawatch.com/news/ZTS/zoetis-launches-portela-reflovetmab-canada-eu BiopharmaWatch en 2026-07-22T11:30:00.000Z Zoetis Launches Portela® (relfovetmab) in Canada and the European Union https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-plozasiran-phase-3-results BiopharmaWatch en 2026-07-22T11:30:00.000Z Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia https://www.biopharmawatch.com/news/ZLAB/zai-lab-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-22T11:30:00.000Z Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026 https://www.biopharmawatch.com/news/TRIB/trinity-biotech-latch-medical-collaboration-drug-delivery BiopharmaWatch en 2026-07-22T11:30:00.000Z Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology https://www.biopharmawatch.com/news/ZVRA/zevra-therapeutics-q2-2026-financial-results-call BiopharmaWatch en 2026-07-22T11:30:00.000Z Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call https://www.biopharmawatch.com/news/RADX/radiopharm-rad204-phase-1-trial-results BiopharmaWatch en 2026-07-22T11:05:00.000Z Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy https://www.biopharmawatch.com/news/QURE/uniqure-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-22T11:05:00.000Z uniQure to Announce Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/UTHR/united-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-07-22T11:00:00.000Z United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026 https://www.biopharmawatch.com/news/CNMD/conmed-airseal-robotic-solution-expansion BiopharmaWatch en 2026-07-22T11:00:00.000Z CONMED Corporation Announces Expanded Indication for the FDA Cleared AirSeal® Robotic Solution for Use with the Intuitive da Vinci 5 Hex Cannula https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-q2-results-2023 BiopharmaWatch en 2026-07-22T11:00:00.000Z Healthcare Services Group Reports Second Quarter Results https://www.biopharmawatch.com/news/CSTL/castle-biosciences-canaccord-genuity-conference-2026 BiopharmaWatch en 2026-07-22T11:00:00.000Z Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/CRIS/curis-positive-emavusertib-update BiopharmaWatch en 2026-07-22T11:00:00.000Z Curis Announces Positive Emavusertib Update https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-btig-biotechnology-conference-2026 BiopharmaWatch en 2026-07-22T11:00:00.000Z Avalo Therapeutics to Participate in the BTIG Biotechnology Conference https://www.biopharmawatch.com/news/OKYO/okyo-pharma-cmo-share-purchase BiopharmaWatch en 2026-07-22T11:00:00.000Z OKYO Pharma Announces Purchase of Shares by Chief Medical Officer https://www.biopharmawatch.com/news/LAB/standard-bi-tools-q2-2026-results-announcement BiopharmaWatch en 2026-07-22T11:00:00.000Z Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/RADX/radiopharm-theranostics-phase-2b-trial-results-rad101 BiopharmaWatch en 2026-07-22T11:00:00.000Z Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases https://www.biopharmawatch.com/news/GERN/geron-announces-q2-2026-financial-results BiopharmaWatch en 2026-07-22T11:00:00.000Z Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/BCRX/biocryst-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-22T11:00:00.000Z BioCryst to Report Second Quarter 2026 Financial Results on August 5 https://www.biopharmawatch.com/news/BDX/mike-garrison-retirement-bd BiopharmaWatch en 2026-07-22T10:55:00.000Z Mike Garrison to Retire from BD https://www.biopharmawatch.com/news/RPRX/neurimmune-sells-royalty-interest-cliramitug-royalty-pharma BiopharmaWatch en 2026-07-22T10:50:00.000Z Neurimmune sells a portion of its royalty interest in cliramitug to Royalty Pharma https://www.biopharmawatch.com/news/PHVS/bradykinin-b2-receptor-therapeutic-target BiopharmaWatch en 2026-07-22T10:50:00.000Z Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema https://www.biopharmawatch.com/news/SMMT/ivonescimab-phase-iii-harmoni-results BiopharmaWatch en 2026-07-22T10:30:00.000Z Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study https://www.biopharmawatch.com/news/RMTI/rockwell-medical-advances-leadership BiopharmaWatch en 2026-07-22T10:00:00.000Z Rockwell Medical Advances Quality and Regulatory Leadership https://www.biopharmawatch.com/news/NTRA/signatera-mrd-outperformed-amerk-merkel-cell-carcinoma BiopharmaWatch en 2026-07-22T10:00:00.000Z Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-flamingo-01-uk-expansion BiopharmaWatch en 2026-07-22T10:00:00.000Z Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom https://www.biopharmawatch.com/news/BLFS/repligen-acquire-biolife-solutions-cell-therapy BiopharmaWatch en 2026-07-22T10:00:00.000Z Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media https://www.biopharmawatch.com/news/RDNT/radnet-second-quarter-2026-financial-results-call BiopharmaWatch en 2026-07-22T10:00:00.000Z RadNet, Inc. Announces Date of its Second Quarter 2026 Financial Results Conference Call https://www.biopharmawatch.com/news/BDSX/biodesix-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-22T10:00:00.000Z Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/OLMA/greenluck-withdrawal-pending-meaning BiopharmaWatch en 2026-07-22T08:56:26.000Z Understanding The Greenluck Withdrawal Pending Meaning https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-upsized-public-offering BiopharmaWatch en 2026-07-22T02:46:00.000Z Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock https://www.biopharmawatch.com/news/PMI/picard-medical-reverse-stock-split-nyse-compliance BiopharmaWatch en 2026-07-22T00:48:00.000Z Picard Medical Announces Reverse Stock Split Following Stockholder Approval to Support Continued NYSE American Listing Compliance https://www.biopharmawatch.com/news/GSK/jideytro-approval-ros1-positive-nsclc BiopharmaWatch en 2026-07-22T00:00:00.000Z Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ROS1 selective inhibitor,...